Generation of quality-controlled SARS-CoV-2 variant stocks
© 2023. Springer Nature Limited..
One of the main challenges in the fight against coronavirus disease 2019 (COVID-19) stems from the ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into multiple variants. To address this hurdle, research groups around the world have independently developed protocols to isolate these variants from clinical samples. These isolates are then used in translational and basic research-for example, in vaccine development, drug screening or characterizing SARS-CoV-2 biology and pathogenesis. However, over the course of the COVID-19 pandemic, we have learned that the introduction of artefacts during both in vitro isolation and subsequent propagation to virus stocks can lessen the validity and reproducibility of data. We propose a rigorous pipeline for the generation of high-quality SARS-CoV-2 variant clonal isolates that minimizes the acquisition of mutations and introduces stringent controls to detect them. Overall, the process includes eight stages: (i) cell maintenance, (ii) isolation of SARS-CoV-2 from clinical specimens, (iii) determination of infectious virus titers by plaque assay, (iv) clonal isolation by plaque purification, (v) whole-virus-genome deep-sequencing, (vi and vii) amplification of selected virus clones to master and working stocks and (viii) sucrose purification. This comprehensive protocol will enable researchers to generate reliable SARS-CoV-2 variant inoculates for in vitro and in vivo experimentation and will facilitate comparisons and collaborative work. Quality-controlled working stocks for most applications can be generated from acquired biorepository virus within 1 month. An additional 5-8 d are required when virus is isolated from clinical swab material, and another 6-7 d is needed for sucrose-purifying the stocks.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Nature protocols - 18(2023), 12 vom: 13. Dez., Seite 3821-3855 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
de Vries, Maren [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 07.12.2023 Date Revised 07.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41596-023-00897-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36326387X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36326387X | ||
| 003 | DE-627 | ||
| 005 | 20231226092953.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41596-023-00897-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1210.xml |
| 035 | |a (DE-627)NLM36326387X | ||
| 035 | |a (NLM)37833423 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a de Vries, Maren |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Generation of quality-controlled SARS-CoV-2 variant stocks |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.12.2023 | ||
| 500 | |a Date Revised 07.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. Springer Nature Limited. | ||
| 520 | |a One of the main challenges in the fight against coronavirus disease 2019 (COVID-19) stems from the ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into multiple variants. To address this hurdle, research groups around the world have independently developed protocols to isolate these variants from clinical samples. These isolates are then used in translational and basic research-for example, in vaccine development, drug screening or characterizing SARS-CoV-2 biology and pathogenesis. However, over the course of the COVID-19 pandemic, we have learned that the introduction of artefacts during both in vitro isolation and subsequent propagation to virus stocks can lessen the validity and reproducibility of data. We propose a rigorous pipeline for the generation of high-quality SARS-CoV-2 variant clonal isolates that minimizes the acquisition of mutations and introduces stringent controls to detect them. Overall, the process includes eight stages: (i) cell maintenance, (ii) isolation of SARS-CoV-2 from clinical specimens, (iii) determination of infectious virus titers by plaque assay, (iv) clonal isolation by plaque purification, (v) whole-virus-genome deep-sequencing, (vi and vii) amplification of selected virus clones to master and working stocks and (viii) sucrose purification. This comprehensive protocol will enable researchers to generate reliable SARS-CoV-2 variant inoculates for in vitro and in vivo experimentation and will facilitate comparisons and collaborative work. Quality-controlled working stocks for most applications can be generated from acquired biorepository virus within 1 month. An additional 5-8 d are required when virus is isolated from clinical swab material, and another 6-7 d is needed for sucrose-purifying the stocks | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Sucrose |2 NLM | |
| 650 | 7 | |a 57-50-1 |2 NLM | |
| 700 | 1 | |a Ciabattoni, Grace O |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez-Rodriguez, Bruno A |e verfasserin |4 aut | |
| 700 | 1 | |a Crosse, Keaton M |e verfasserin |4 aut | |
| 700 | 1 | |a Papandrea, Dominick |e verfasserin |4 aut | |
| 700 | 1 | |a Samanovic, Marie I |e verfasserin |4 aut | |
| 700 | 1 | |a Dimartino, Dacia |e verfasserin |4 aut | |
| 700 | 1 | |a Marier, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Mulligan, Mark J |e verfasserin |4 aut | |
| 700 | 1 | |a Heguy, Adriana |e verfasserin |4 aut | |
| 700 | 1 | |a Desvignes, Ludovic |e verfasserin |4 aut | |
| 700 | 1 | |a Duerr, Ralf |e verfasserin |4 aut | |
| 700 | 1 | |a Dittmann, Meike |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature protocols |d 2006 |g 18(2023), 12 vom: 13. Dez., Seite 3821-3855 |w (DE-627)NLM167398601 |x 1750-2799 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2023 |g number:12 |g day:13 |g month:12 |g pages:3821-3855 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41596-023-00897-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2023 |e 12 |b 13 |c 12 |h 3821-3855 | ||